As of 2026, women remain underrepresented in STEM fields, but initiatives like the Women and Underrepresented Minorities in ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Around a third of adults in England are now living with obesity, and new cases are rising most quickly in younger adults, ...

When Sam Neill announced he had received CAR-T cell therapy and was in remission, the coverage was celebratory and rightly so ...

The European Commission has opened an investigation into a marketing campaign run by Sanofi for an influenza vaccine, and whether it disparaged its only rival in the market. Specifically, it is ...

Hundreds of women with aggressive cervical cancer are to be offered MSD's Keytruda on the NHS in England, in the second ...

Pfizer's Ibrance has become the first CDK4/6 inhibitor to be approved by the FDA for a challenging subtype of breast cancer ...

Earlier this year, when US telehealth giant Hims & Hers first unveiled plans to acquire its Australian rival Eucalyptus for a ...

Ollin Biosciences has followed its $100 million Series A last year with a massive $330 million second round that will fuel ...

Around 90 women with advanced cervical cancer in the UK could be eligible for treatment with Regeneron's immunotherapy ...

The US pharmaceutical industry is entering a new phase of supply chain transformation. Regulatory pressure, geopolitical ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...